Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT-1
ELECTRON Trial (Arms 12-17 & 22)

## ELECTRON Trial (Arms 12-17 & 22): Features

<table>
<thead>
<tr>
<th><strong>Design</strong></th>
<th>Open-label, phase 2, using sofosbuvir plus [ledipasvir or GS-9669] with or without ribavirin in treatment-naïve and treatment-experienced GT1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Setting</strong></td>
<td>Two hepatitis treatment centers in New Zealand</td>
</tr>
</tbody>
</table>
| **Entry Criteria** | - Chronic HCV Genotype 1  
- HCV RNA > 50,000 IU/mL  
- Age > 18 |
| **Patient Characteristics (range in different treatment arms)** | - N = 113 patients enrolled  
- Three of seven groups were treatment naïve  
- Four of seven groups were treatment experienced with prior null response  
- Two groups of seven groups were treatment experienced and cirrhotic  
- Three treatment arms used fixed dose ledipasvir-sofosbuvir |
| **Primary End-Point** | SVR12 |
Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT1 ELECTRON Trial Arms (12-17 & 22): Design

**Abbreviations**: LDV = ledipasvir; SOF = sofosbuvir; RBV = ribavirin

**Drug Dosing**
- Sofosbuvir: 400 mg once daily
- Ledipasvir: 90 mg once daily
- GS-9669 = 500 mg once daily
- Ledipasvir-sofosbuvir (90/400 mg): fixed dose combination one pill once daily
- Ribavirin (weight-based and divided bid): 1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg
Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT1 ELECTRON Trial (Arms 12-17 & 22): Results

ELECTRON TRIAL, SVR 12 by Treatment Regimen

<table>
<thead>
<tr>
<th>Treatment Regimen</th>
<th>Noncirrhotic Treatment-Naive</th>
<th>Noncirrhotic Prior Null Responder</th>
<th>Cirrhotic Prior Null Responder</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDV + SOF + RBV</td>
<td>100% (25/25)</td>
<td>100% (10/10)</td>
<td>100% (9/9)</td>
</tr>
<tr>
<td>SOF + GS-9669 + RBV (6 wks)</td>
<td>92% (23/25)</td>
<td>100% (10/10)</td>
<td>70% (7/10)</td>
</tr>
<tr>
<td>LDV-SOF + RBV</td>
<td>68% (17/25)</td>
<td>9% (2/25)</td>
<td>100% (9/9)</td>
</tr>
</tbody>
</table>

*All regimens 12 weeks except treatment-naïve LDV-SOF + Ribavirin= 6 week regimen

**Conclusions:** “The combination of sofosbuvir and a second direct-acting antiviral agent is highly effective in treatment-naïve patients with HCV genotype 1 infection and in patients that did not respond to previous treatment.”
This slide deck is from the University of Washington’s *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online  
[www.hepatitisc.uw.edu](http://www.hepatitisc.uw.edu)

Hepatitis Web Study  

Funded by a grant from the Centers for Disease Control and Prevention.